Literature DB >> 15659045

Effects of selective dopamine receptor subtype agonists on cardiac contractility and regional haemodynamics in rats.

James S Polakowski1, Jason A Segreti, Bryan F Cox, Gin C Hsieh, Teodozyj Kolasa, Robert B Moreland, Jorge D Brioni.   

Abstract

1. Activation of dopamine (DA) receptors produces cardiovascular responses such as vasodilation and hypotension. However, knowledge of the role of specific dopamine receptor subtypes (especially D3 and D4) in the cardiovascular system is limited. The objective of the present study was to characterize the haemodynamic and cardiac responses to agonists with selectivity for D1, D2, D3 and D4 receptor subtypes. 2. Inactin-anaesthetized rats were instrumented to measure regional haemodynamic and cardiac contractility responses with slow intravenous infusion of agonists. 3. Fenoldopam (a D1 receptor agonist) decreased (P < 0.05) renal vascular resistance beginning at a dose of 3 micromol/kg. Infusion of PNU-95666E (a D2 receptor agonist) produced dose-dependent decreases (P < 0.05) in mean arterial pressure (MAP), heart rate (HR) and hindquarter vascular resistance (HQVR). Administration of BP897 (a partial D3 receptor agonist) decreased (P < 0.05) MAP and HQVR at 3 micromol/kg. PD168077 (a D4 receptor agonist) caused significant increases in HQVR at 1 micromol/kg. None of the compounds tested elicited significant changes in cardiac contractility. 4. Using selective agonists of dopamine receptor subtypes, the present studies characterize distinct cardiovascular effects in anaesthetized rats. Consistent with its well-defined effects as a D1 receptor agonist, fenoldopam administration resulted in renal vasodilation. Similar to earlier studies using the non-selective D2-like receptor agonist quinpirole, selective agonism at the D2 receptor using PNU-95666E resulted in bradycardia, hindquarter vasodilation and decreases in arterial pressure. Partial agonism at the D3 receptor with BP897 had no effect on heart rate, but did produce depressor responses driven by decreases in HQVR. Conversely, agonism of the D4 receptor using PD168077 resulted in modest hindquarter vasoconstriction that was not dose dependent. Hence, by comparison, agonism of the D4 receptor has little effect in the cardiovascular system of the rat relative to the other dopamine receptor subtype agonists tested.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15659045     DOI: 10.1111/j.1440-1681.2004.04095.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  9 in total

1.  Activation of D4 dopamine receptor decreases angiotensin II type 1 receptor expression in rat renal proximal tubule cells.

Authors:  Ken Chen; Kun Deng; Xiaoyan Wang; Zhen Wang; Shuo Zheng; Hongmei Ren; Duofen He; Yu Han; Laureano D Asico; Pedro A Jose; Chunyu Zeng
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

Review 2.  Dopamine and G protein-coupled receptor kinase 4 in the kidney: role in blood pressure regulation.

Authors:  Pedro A Jose; Patricio Soares-da-Silva; Gilbert M Eisner; Robin A Felder
Journal:  Biochim Biophys Acta       Date:  2010-02-12

3.  Binding of the Dual-Action Anti-Parkinsonian Drug AG-0029 to Dopamine D2 and Histamine H3 Receptors: A PET Study in Healthy Rats.

Authors:  Nafiseh Ghazanfari; Aren van Waarde; Janine Doorduin; Jürgen W A Sijbesma; Maria Kominia; Martin Koelewijn; Khaled Attia; David Vállez-García; Antoon T M Willemsen; André Heeres; Rudi A J O Dierckx; Ton J Visser; Erik F J de Vries; Philip H Elsinga
Journal:  Mol Pharm       Date:  2022-06-22       Impact factor: 5.364

4.  Vitamin d receptor activation mitigates the impact of uremia on endothelial function in the 5/6 nephrectomized rats.

Authors:  J Ruth Wu-Wong; William Noonan; Masaki Nakane; Kristin A Brooks; Jason A Segreti; James S Polakowski; Bryan Cox
Journal:  Int J Endocrinol       Date:  2010-02-10       Impact factor: 3.257

5.  The role of dopamine D2, but not D3 or D4, receptor subtypes, in quinpirole-induced inhibition of the cardioaccelerator sympathetic outflow in pithed rats.

Authors:  A H Altamirano-Espinoza; A González-Hernández; G Manrique-Maldonado; B A Marichal-Cancino; I Ruiz-Salinas; C M Villalón
Journal:  Br J Pharmacol       Date:  2013-11       Impact factor: 8.739

Review 6.  Dysregulation of dopamine-dependent mechanisms as a determinant of hypertension: studies in dopamine receptor knockout mice.

Authors:  Chunyu Zeng; Ines Armando; Yingjin Luo; Gilbert M Eisner; Robin A Felder; Pedro A Jose
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-12-14       Impact factor: 4.733

7.  Consequences of peripheral chemoreflex inhibition with low-dose dopamine in humans.

Authors:  Piotr Niewinski; Stanislaw Tubek; Waldemar Banasiak; Julian F R Paton; Piotr Ponikowski
Journal:  J Physiol       Date:  2014-01-06       Impact factor: 5.182

Review 8.  Renal Dopamine Receptors and Oxidative Stress: Role in Hypertension.

Authors:  Jian Yang; Van Anthony M Villar; Pedro A Jose; Chunyu Zeng
Journal:  Antioxid Redox Signal       Date:  2020-05-29       Impact factor: 8.401

Review 9.  Altered pharmacological effects of adrenergic agonists during hypothermia.

Authors:  Erik Sveberg Dietrichs; Georg Sager; Torkjel Tveita
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2016-12-05       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.